HEALTHglobal

STAT+: Novartis picks up experimental breast cancer therapy for $2B

Single source

Updated 3 hours ago

First seen March 20, 2026 20:49:28

Stay on top of this story

Follow the names and topics behind it.

Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.

Create a free account to sync your watchlist, saved stories, and alerts across devices.

Looking to bolster its pipeline, Novartis is buying a breast cancer drug candidate for $2 billion from Delaware-based Synnovation Therapeutics.